Microbot Medical Partners with Baptist Hospital of Miami to Participate in its Pivotal Human Clinical Trial
03 Luglio 2024 - 2:20PM
Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative
LIBERTY® Endovascular Robotic Surgical System, today announces it
has received Institutional Review Board approval and signed a
Clinical Trial Agreement with Baptist Hospital of Miami, which
includes Miami Cardiac & Vascular Institute and Miami Cancer
Institute. This is the second announced site that will
participate in the clinical trial for Microbot’s LIBERTY as part of
its Investigational Device Exemption (“IDE”). The
Company had recently announced Brigham and Women's Hospital as
another participating site.
The principal investigator at Baptist Hospital
of Miami will be Ripal Gandhi, MD, FSVM. “I am very excited to
participate in the trial. I believe this technology has the
potential to change how we perform endovascular procedures,” said
Dr. Gandhi.
“We believe the interest in the LIBERTY
technology is overwhelming, as evident by the fast pace of
enrolling and activating leading sites into the pivotal trial since
we announced the IDE. We are excited for our partnership with
Baptist Hospital of Miami, which is one of the leading hospitals in
the United States,” commented Harel Gadot, CEO, President and
Chairman of Microbot Medical.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a
clinical- stage medical device company that specializes in
transformational micro-robotic technologies, with the goals of
improving clinical outcomes for patients and increasing
accessibility through the natural and artificial lumens within the
human body.
The Investigational LIBERTY® Endovascular
Robotic Surgical System aims to improve the way surgical robotics
are being used in endovascular procedures today, by eliminating the
need for large, cumbersome, and expensive capital equipment, while
reducing radiation exposure and physician strain. The Company
believes the LIBERTY® Endovascular Robotic Surgical System’s remote
operation has the potential to be the first system to democratize
endovascular interventional procedures.
Further information about Microbot Medical is available at
http://www.microbotmedical.com.
Safe Harbor
Statements to future financial and/or operating
results, future growth in research, technology, clinical
development, and potential opportunities for Microbot Medical Inc.
and its subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as “will,” “believes,” “plans,” “anticipates,” “expects” and
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, market conditions,
risks inherent in the development and/or commercialization of the
LIBERTY® Endovascular Robotic Surgical System, the outcome of its
studies to evaluate the LIBERTY® Endovascular Robotic Surgical
System, uncertainty in the results of pre-clinical and clinical
trials or regulatory pathways and regulatory approvals, including
whether the Company’s pivotal study in humans is successful, any
failure or inability to recruit physicians and clinicians to serve
as primary investigators to conduct regulatory studies which could
adversely affect or delay such studies, disruptions resulting from
new and ongoing hostilities between Israel and the Palestinians and
other neighboring countries, any lingering uncertainty resulting
from the COVID-19 pandemic, need and ability to obtain future
capital, and maintenance of intellectual property rights.
Additional information on risks facing Microbot Medical can be
found under the heading “Risk Factors” in Microbot Medical’s
periodic reports filed with the Securities and Exchange Commission
(SEC), which are available on the SEC’s web site at www.sec.gov.
Microbot Medical disclaims any intent or obligation to update these
forward-looking statements, except as required by law.
Investor Contact:
Michal Efraty
IR@microbotmedical.com
Grafico Azioni Microbot Medical (NASDAQ:MBOT)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Microbot Medical (NASDAQ:MBOT)
Storico
Da Lug 2023 a Lug 2024